AstraZeneca has secured a significant deal in the competitive field of cancer research, specifically focusing on a target known as KRAS G12D. AstraZeneca paid a whopping $24 million upfront to get a key asset in this area, showing their commitment to staying strong in the ever-changing world of cancer treatment.
The collaborative endeavor has bestowed upon AstraZeneca exclusive global licensing rights to UA022, a small molecule inhibitor designed to target the once-deemed undruggable KRAS oncogene.
Originating from the laboratories of Chinese biotech Usynova, UA022 underwent meticulous preclinical development in collaboration with esteemed partners, including WuXi AppTec. AstraZeneca’s offer, which encompasses the potential for additional payments amounting to a staggering $395 million in milestones, proved too enticing for Usynova to decline.
This licensing agreement catapults AstraZeneca into a domain already bustling with activity, as several pharmaceutical companies vie for supremacy. Notable contenders in the KRAS inhibitor space include Amgen’s Lumakras and Mirati Therapeutics’ Krazati, which predominantly target G12C-mutated cancers, constituting approximately 14% of all KRAS-driven malignancies.
AstraZeneca’s strategic pivot towards G12D mutations, which are more prevalent, aligns with the ongoing endeavors of other pharmaceutical players seeking to tap into this expansive market opportunity.
The pharmaceutical landscape is rife with G12D-focused initiatives, with Silenseed having advanced a siRNA candidate to phase 2 trials in 2018, though its current status remains uncertain.
Mirati is actively navigating the intricate landscape of phase 1/2 trials with its own G12D asset. Concurrently, other major players such as Astellas, Jiangsu HengRui Medicine, and Revolution Medicines are rigorously evaluating G12D candidates in human trials. In contrast, UA022, the latest addition to AstraZeneca’s burgeoning portfolio, is poised to enter the clinical trial phase.
This strategic move reaffirms AstraZeneca’s commitment to the KRAS domain, which traces back to 2012 when the company licensed AZD4785, an anti-KRAS antisense oligonucleotide, from Ionis.
Despite the setback of AZD4785 stalling at phase 1, AstraZeneca’s research teams persisted in their pursuit of the KRAS target, eventually leading to the discovery of the KRAS G12C inhibitor AZD4625.
This molecule underwent further refinement, evolving into the promising clinical candidate AZD4747. While AstraZeneca may be trailing behind leaders in the G12C sector, its unique proposition lies in the potential of AZD4747 to penetrate the central nervous system, providing a distinctive advantage in this competitive landscape.
This recent strategic maneuver to secure a KRAS G12D inhibitor once again directs AstraZeneca’s attention to China.
In the current year, the pharmaceutical juggernaut has orchestrated a series of collaborations with Chinese partners, cementing alliances with Eccogene, LaNova Medicines, and KYM Biosciences.
